Numinus provides information about the integration of new acquisitions and offers customer financing options
Numinus Wellness Inc. NUMIF recently acquired psychedelics company Novamind and successfully integrates its activities: US clinics performed solidly while client appointments increased during the fourth fiscal quarter (the three months ended August 31, 2022).
number mental health services These include traditional therapy, counseling, transcranial magnetic stimulation (TMS), ketamine-assisted therapy (KAT), and Canada’s SAP-approved cases of psychedelics-assisted therapy.
In August, clinics across Canada and the US held more than 6,000 patient appointments combined, a 25% increase from July. In particular, the eight US wellness clinics received nearly five thousand clients. 15% of sych customers were new patients, a 22% increase from the previous month.
to the necessary treatmentsKetamine sessions at the company’s US clinics (including KAT, Spravato and Ketamine Medicine) increased 35% in August compared to July to 1,520 appointments, while demand for TMS services increased 23% to 725 appointments in August compared to July .
Former Novamind Clinical Trials Management Division Clinical research from cedar maintains positive operational growth: During Numinus’ fiscal fourth quarter, it recruited 178 clinical trial participants for 16 third-party clinical trials, representing a 19% increase in clinical trial participation compared to fiscal third quarter .
Additionally, a new financing option is available to Canadian patients through iFinance, with interest rates based on the applicant’s credit history. Once approved, Numinus will provide the therapy services and collect full payment from iFinance upon completion of the treatment plan.
Numinus believes the new option will improve the accessibility of its traditional therapy and ketamine-assisted therapy to a broader patient population.
Tryp Therapeutics retains IMS Investor Relations
Manufacturer of psilocybin-based compounds Tryp Therapeutics Inc.
